29 related articles for article (PubMed ID: 17638066)
1. The early days of letrozole.
Bhatnagar AS
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):3-5. PubMed ID: 17912632
[No Abstract] [Full Text] [Related]
2. 'Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer'.
J Pathol Clin Res; 2019 Jul; 5(3):213. PubMed ID: 31334921
[No Abstract] [Full Text] [Related]
3. Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER
Dowsett M; Kilburn L; Rimawi MF; Osborne CK; Pogue-Geile K; Liu Y; Jacobs SA; Finnigan M; Puhalla S; Dodson A; Martins V; Cheang M; Perry S; Holcombe C; Turner N; Swift C; Bliss JM; Johnston S;
Clin Cancer Res; 2022 Jan; 28(1):163-174. PubMed ID: 34645649
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Jansen MP; Sas L; Sieuwerts AM; Van Cauwenberghe C; Ramirez-Ardila D; Look M; Ruigrok-Ritstier K; Finetti P; Bertucci F; Timmermans MM; van Deurzen CH; Martens JW; Simon I; Roepman P; Linn SC; van Dam P; Kok M; Lardon F; Vermeulen PB; Foekens JA; Dirix L; Berns EM; Van Laere S
Mol Oncol; 2015 Jun; 9(6):1218-33. PubMed ID: 25771305
[TBL] [Abstract][Full Text] [Related]
5. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
Beelen K; Zwart W; Linn SC
Nat Rev Clin Oncol; 2012 Sep; 9(9):529-41. PubMed ID: 22825374
[TBL] [Abstract][Full Text] [Related]
6. GenDrux: a biomedical literature search system to identify gene expression-based drug sensitivity in breast cancer.
Crasto C; Luo D; Yu F; Forero A; Chen D
BMC Med Inform Decis Mak; 2011 May; 11():28. PubMed ID: 21545721
[TBL] [Abstract][Full Text] [Related]
7. Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2.
Winter N; Nimzyk R; Bösche C; Meyer A; Bullerdiek J
PLoS One; 2011 Apr; 6(4):e18837. PubMed ID: 21533145
[TBL] [Abstract][Full Text] [Related]
8. Letrozole.
Dellapasqua S; Colleoni M
Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):251-9. PubMed ID: 20095792
[TBL] [Abstract][Full Text] [Related]
9. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Urruticoechea A; Aguilar H; Solé X; Capellà G; Martin LA; Dowsett M; Germà-Lluch JR
Breast Cancer Res Treat; 2008 Jun; 109(3):463-70. PubMed ID: 17638066
[TBL] [Abstract][Full Text] [Related]
11. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
12. Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
Chottanapund S; Van Duursen MB; Navasumrit P; Hunsonti P; Timtavorn S; Ruchirawat M; Van den Berg M
Toxicol In Vitro; 2014 Oct; 28(7):1215-21. PubMed ID: 24929094
[TBL] [Abstract][Full Text] [Related]
13. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
